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1. Introduction  
The large surface area and the short diffusion distance from capillaries of the blood brain 
barrier (BBB) to the neurons facilitate the drugs and nutrients access to the brain. 
Penetration of chemicals to the BBB occurs using a combination of intra and intercellular 
passages. Tight junctions regulate the intracellular passage of molecules according to their 
physico- chemical properties (e.g. lipophilicity, ionisation and polarity), where inter cellular 
penetration is regulated by influx and efflux transporters, endocytosis and passive diffusion. 
Poor pharmacokinetic properties (absorption, distribution, metabolism and excretion) and 
toxicity are responsible for most of the failures in drug discovery projects. This problem is 
more evident for CNS drugs because of the restrict barrier function of blood brain barrier. 
The CNS drug discovery attracted more attentions since the diseases pattern has been 
changed during recent decades and aging disorders are one of the major health problems. 
Drug exposure is controlled by plasma pharmacokinetic properties of drug which are 
different from brain pharmacokinetic and can be studied using common pharmacokinetic 
studies, where BBB permeability depends on physicochemical properties of drug compound 
and physiologic function of the BBB (physical barrier, transport, metabolic, …) and need 
special study techniques. In this chapter, fundamentals of BBB, permeation mechanisms, 
penetration measurement methods and penetration prediction methods are discussed. 
2. Fundamentals of BBB 
2.1 Cellular properties of Blood Brain Barrier 
BBB consisted of a monolayer of brain micro vascular endothelial cells (BMVEC) joined 
together by much tighter junctions than peripheral vessels and formed a cellular membrane 
which known as the main physical barrier of BBB (Abbott, 2005; Cardoso et.al., 2010). The 
main characteristics of this cellular membrane are, uniform thickness, no fenestrae, low 
pinocytotic activity, continues basement membrane and negative surface charge. In addition 
to the BMVECs, the neurovascular unit consisted of the capillary basement membrane, 
pericytes, astrocytes and microglia. The BMVECs are surrounded by a basement membrane 
which composed of structural proteins (collagen and elastin), specialized proteins 
(fibronectin and laminin) and proteoglycans. This structural specificity gives the basement 
membrane a cell establishment role. Pericytes are cellular constituents of microvessels 
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including capillaries and post capillary venules that covered about 22-32% of the capillaries 
and shared the same basement membrane. Pericytes are responsible for a wide variety of 
structural and non-structural tasks in BBB. In summary they synthesis some of structural 
and signalling proteins and they are involved in the BMVECs proliferation, migration and 
differentiation. More details and references about pericytes role in BBB can be found in the 
literature (Cardoso et al., 2010). Fine lamellae closely opposed to the outer surface of the 
capillary endothelium and respective basement membrane formed by astrocytes end feet. 
Like pericytes, astrocytes involve in various functional and structural properties of 
neurovascular unit.  
Microglia is immunocompetent cells of the brain that continuously survey local micro 
environment with highly motile extensions and change the phenotype in response to the 
homeostatic disturbance of the CNS (Prinz & Mildner, 2011). The interactions of brain micro 
vascular endothelial cells with basement membrane, neighbouring glial cells (microglia and 
astrocytes), neurons and perivascular pericytes leads to specific brain micro vascular 
biology. Presence of matrix adhesion receptors and signalling proteins form an extensive 
and complex matrix which is essential for maintenance of the BBB (Cardoso et al., 2010). 
Figure 1 shows a schematic illustration of neurovascular unit and BBB cellular components. 
 
 
Fig. 1. Schematic illustration of the neurovascular unit and BBB cellular components 
adopted from (Cardoso et al., 2010). 
2.2 Molecular properties of BBB 
The BMVECs assembly are regulated by molecular constituents of tight junctions, adherence 
junctions and signalling pathways. Tight junctions are highly dynamic structures which are 
responsible for the barrier properties of BBB. Apical region of the endothelial cells sealed 
together by tight junctions and paracellular permeability of BMVECs are limited by them. 
Structurally tight junctions formed by interaction of integral transmembrane proteins with 
neighbouring plasma membrane. Among these proteins junction adhesion molecules, 
claudins and occludins (inter membrane) which bind to the cytoplasmic proteins (e.g. 
zonula occludens, cinguline, …) are well studied and their role in tight junctions and BBB 
have been evaluated (Figure 2). Beyond the main role in physical restriction of BBB, other 
functions such as control of gene expression, cell proliferation and differentiation have been 
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suggested for tight junctions. Below the tight junctions, actin filaments (including cadherins 
and catenins) linked together and form a belt of adherence junctions. In addition to the 
contribution in the barrier function some other events such as adhesion of BMVECs to each 
other, the contact inhibition during vascular growth, the initiation of cell polarity and the 
regulation of paracellular permeability have been suggested for adherence junctions. A 
dynamic interaction between tight junctions and adherence junctions through signalling 
pathways regulate the permeability of BBB. These signalling routes mainly involve protein 
kinases, members of mitogen – activated protein kinases, endothelial nitric oxide synthase 
and G-proteins. Dynamic interactions between these pathways control the opening and 
closing of the paracellular route for fluids, proteins and cells to move across the endothelial 
cells through two main types of signal transduction procedures (e.g. signals from cell 
interior to tight junctions to guide their assembly and regulate their permeability, signals 
transmitted from tight junctions to cell interior to modulate gene expression, proliferation 
and differentiation). The molecular mechanisms of these interactions can be found in the 
literature (Ballab et al., 2004; Abbott et al., 2006). In addition to the proteins with enzymatic 
activities, there are other specific proteins (drug efflux transporters, multi drug resistance 
proteins, organic anion transporting polypeptides) work as BBB transporters which are 
responsible for rapid efflux of xenobiotics from the CNS (Losscher & Potschka, 2005) and 
delivery of the essential nutrients and transmitters to the brain.  
The combined effect of the special cellular and molecular properties of central nervous 
system result in the specific barrier functions of BBB which is important for preventing CNS 
from harmful xenobiotics. Because of these properties drug delivery to the CNS is among 
the most challenging drug development areas. In order to develop successful drug 
candidates for CNS disorders drug uptake mechanisms should be studied. In the next 
section, these mechanisms are briefly reviewed. 
 
 
Fig. 2. Tight junctions and adherent junctions. 
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3. BBB permeation mechanisms 
Like other cellular membranes in the body, permeation through BBB can occur by passive 
diffusion, endocytosis and active transport (Diagram 1). Combined effects of the mentioned 
mechanisms modulate the compound (e.g. Drugs) penetration to the brain. 
 
 
Diagram 1. Main permeation mechanisms in the brain.  
3.1 Passive diffusion 
A limited number of drugs and drug like compounds with high lipophilicity and low 
molecular size can penetrate to the brain mainly by passive diffusion. In order to overcome 
the surface tension difference between a compound and cellular membrane, physical work 
is needed and the smaller molecules will need less work. The uncharged forms of the weak 
acidic and basic compounds have higher permeability rate in comparison with charged 
molecules in physiologic pH of brain. The charged forms possess hydrophilic characteristics 
and hydrophilic drugs distribute within blood and cannot cross the endothelial cells and 
excreted from brain parenchyma. Therefore, the molecules with higher fraction of 
uncharged form in physiologic pH have higher permeability rate (Fischer et al., 1998). 
Passive diffusion occurs via two mechanisms (Figure 3):  
- Free diffusion in which some compounds move freely paracellularly (e.g. sucrose) 
between cells to a limited extent due to tight junctions or transcellularly (transcytosis) 
across the cells for lipophilic substances (e.g. ethanol) (Alam et al., 2010). These 
mechanisms are non-competitive, nonsaturable and occur in downhill concentration 
direction.  
- Facilitated diffusion in which target compounds bind to a specific membrane protein and 
carry to the other side of the membrane through conformation change of the protein. This 
mechanism is a form of carrier mediated endocytosis which occurs from high to low 
concentration like free diffusion and contributes for transport of some amino acids, 
nucleosides, small peptides, mono-carboxylates and glutathione (Alam et al., 2010). 
BBB 
permeation  
Passive Diffusion
Active transport 
Free
Facilitated
Endocytosis
Efflux 
Influx
Bulk phase  
Facilitated
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Fig. 3. Free and facilitated passive diffusion. 
3.2 Endocytosis 
In this method, substances (e.g. macromolecules) are engulfed by membrane and pass 
through the cell by vesicles and release in the other side (Kerns & Di, 2008). Endocytosis 
occurs via two main methods: bulk phase endocytosis (fluid phase or pinocytosis) and 
mediated or facilitated endocytosis (receptor and absorptive mediated). Fluid phase 
endocytosis is a nonsaturable, non-competitive and non-specific method for uptake of extra 
cellular fluids which is temperature and energy dependent.  
Receptor mediated endocytosis facilitates the larger essential molecules uptake selectively 
using specific receptors present in luminal membrane. Hormones, growth factors, enzymes 
and plasma proteins are targets for specific receptors (Pardridge, 2007).  
Absorptive mediated endocytosis is based on an electrostatic interaction between 
negatively charged plasma membrane luminal surfaces (glycocalyx which is a negatively 
charged proteoglycan or glycosaminoglycan) with cationic substances (e.g. peptides) and 
uptake it in a vesicle into the endothelial cell and release it on the other side (Figure 4) 
(Ueno, 2009). 
This has lower affinity and higher capacity than receptor mediated endocytosis (Alam et al., 
2010). Mechanism of vesicle formation (caveolin dependent, dynamin dependent and 
caveolin- dynamin independent) is not discussed in this chapter and more details could be 
found in the literature (Lajoie et al., 2010).  
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Fig. 4. Bulk phase and facilitated endocytosis. 
3.3 Active transport 
Hydrophilic drugs which cannot penetrate the brain through passive diffusion and 
lipophilic drugs which cannot penetrate the brain, in contrast of their suitable characteristics 
for BBB permeation are substrate for drug transporters of the BBB. Also some compounds 
are substrates for transporters and at the same time they are delivered by passive diffusion 
or endocytosis. Drug transporters are integral membrane proteins which is able to carry the 
drug usually against the concentration gradient into and out of the cell.  
The overall exposure of xenobiotics to brain through these transporters depends on their 
location and expression level according to the normal and pathophysiologic conditions. Two 
types of drug transporters according to their driving forces (ATP dependent and ATP 
independent) are known. Active transporters broadly categorized as primary (ATP 
dependent), secondary or tertiary (ATP independent) (Murk et al., 2010).  
There are two types of transporters:  
1. Carrier mediated transporters which express on both the luminal and abluminal 
membranes and operates in both blood to brain and brain to blood directions.  
2. Active efflux transporters which mediate extruding drugs and other compounds from 
brain (Alam et al., 2010). Although the main role of the drug transporters is carrying 
the drugs and other xenobiotics into and out of the brain but they are responsible for 
other cell processes such as inflammation, differentiation of immune cells, cell 
detoxification, lipid trafficking, hormone secretion and development of stem cells 
(Murk et al., 2010).  
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3.3.1 Influx transporters 
Essential hydrophilic nutrients (e.g. glucose, amino acids, fatty acids, organic and inorganic 
ions) reach to brain through influx transporters and receptors. According to the structural 
similarity of the target drug to the biologic molecules; it can be delivered to the brain using 
appropriate transporter. Solute carrier family encodes most of the influx transporters which 
include facilitated, ion coupled and ion exchange transporters that do not need ATP (Eyal et 
al., 2009). These transporters are responsible for uptake of a broad range of substrates 
including glucose, amino acids, nucleosides, fatty acids, minerals and vitamins (Alam et al., 
2010). The most well studied groups of these bidirectional transporters along with their 
properties and activities are summarized in Table 1. 
3.3.2 Efflux transporters 
Efflux occurs in BBB through both passive and active routes in order to detoxify the brain and 
prevent from drugs and xenobiotics exposures. There are several kinds of efflux transporters 
such as ATP binding cassette transporters (ABC), organic anion transport systems, amino acid 
transport systems and so on (Ueno, 2009). ABC transporters are primary active systems which 
are responsible for different efflux activities including P-glycoprotein (P-gp), multi-drug 
resistance proteins (MRPs), and breast cancer related protein (BCRP). P-gp (the most studied 
ABC transporter), located in luminal side of BBB, immediately pump most of the drugs and 
xenobiotics back to the blood and decrease the net penetration to the brain. A broad range of 
drugs, generally including un-conjugated and cationic substances (Table 1) are substrates for 
P-gp, where some of them are able to inhibit P-gp and lead to increased permeability of co-
administered drugs. This fact can be used as a drug delivery strategy to the brain. Along with 
P-gp, MRPs and BCRP are responsible for main part of drug efflux in BBB and their effect are 
dependent to their localization and expression level in normal and pathologic conditions. Over 
expression of these transporters considered as one of the major reasons of pharmacoresistance 
of brain diseases and their inhibition, bypassing and regulating methods are important for 
CNS drug development (Loscher & Potschka, 2005).  
3.4 Metabolism in BBB (Enzymatic barrier) 
Existing enzymes in BBB can be regarded as second barrier after negative surface charge. 
These enzymes involve in disposition of drugs and xenobiotics before entering the 
endothelial cells of capillaries. Alkaline phosphatase, acid phosphatase, 5’-nucleotidase, 
adenosine tri-phosphatase and nucleoside di-phosphatase are among well studied enzymes 
distributed within BBB (Ueno, 2009).  
4. BBB permeation measurement methods 
The rate and the extent of drug transport to the brain are needed for drug discovery studies 
(both peripheral and CNS drugs) and different methods developed in order to study the 
pharmacokinetic profile of drug candidates. BBB permeability depends on physicochemical 
properties of drug compound and physiologic functions of the BBB (physical barrier, 
transport, metabolic pathways) and need special study techniques. These techniques include 
in vivo, in vitro, and in silico methods (Diagram 2) which are complement in most cases and 
researchers are able to define different aspects of drug passage to the brain using these 
methods. 
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Transporter name  Substrates Sample drugs and 
nutrients 
Influx/ 
Efflux 
Organic anion 
transporting 
polypeptides 
Anionic amphipathic molecules 
with molecular weight greater 
than 450 Daltons and a high 
degree of albumin binding 
Fexofenadine, Digoxin, 
Methotrexate  
Influx 
Organic anion 
transporters 
Anionic drugs and nucleotides Benzylpenicillin, 
Valacyclovir, Zidovudine, 
Mercaptopurine, 
Methotrexate, Valproic 
acid 
Influx 
Organic cation 
transporters 
Bidirectional transport of small 
hydrophilic positively charged 
compounds  
Cimetidine , 
Desipramine, Metformin, 
Amantadine, Memantine, 
Cisplatine, Quinin 
Influx / 
Efflux 
System L. Bidirectional transport of large 
neutral amino acids with 
branched or aromatic side 
chains 
L-phenylalanine, L-
tyrosine, L-tryptophan, 
L-lucine, Levodopa, 
-Methyldopa, Baclofen, 
Melphalan, Gabapentin, 
Pregabalin 
Influx / 
Efflux 
Monocarboxylate 
transporters 
HMG-CoA reductase inhibitors 
that contain a carboxylic acid 
moiety  
Simvastatin,  
γ- Hydroxybutyrate 
Influx  
Nucleoside 
transporters  
Purine and pyrimidine 
nucleosides  
Adenosine  Influx  
Hexose transporters Hexose nucleosides Glucose Influx  
Ion transporters Bidirectional transport of small 
ions 
Cl-, Na+, K+, H+, HCO3- Influx / 
Efflux 
P-glycoproteins A broad range of drugs and 
xenobiotics (normally un-
conjugated, cationic substances)
Anti cancer drugs, 
corticoids  
Efflux 
Multi-drug 
resistance proteins 
Drugs and xenobiotics 
(normally conjugated, anionic 
substances) 
Anti cancer and anti HIV 
Drugs 
Efflux 
Breast cancer 
resistant proteins  
Drugs and xenobiotics (overlap 
with P-glycoproteins and multi-
drug resistance proteins) 
Some anti cancer Drugs  Efflux 
Table 1. Some of the well studied influx and efflux transporters of brain. 
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Diagram 2. Brain drug testing methods.  
4.1 BBB permeation data 
4.1.1 Bound and unbound drug concepts  
The drug is available in blood in the free (unbound) and bounded (protein bounded, 
erythrocyte bounded, tissue bounded) forms. The unbound drug molecules equilibrate 
across the BBB and brain. The spaces that these equilibria occur are: blood, interstitial 
fluid, intercellular and intracellular fluids. Figure 5 shows these equilibria schematically. 
The speed of the equilibria to reach the steady state define the rate of drug distribution 
within brain, and the slowest one would be the rate limiting step. For poor CNS 
penetrantes, the BBB permeation or the diffusion of drug molecules within the brain 
tissue is the rate limiting step. Total brain concentration which allow us just to rank drug 
candidates according to their CNS total levels and general CNS penetrability can be 
measured using most of the in vivo methods, while there is just a few methods which are 
able to provide free fractions directly.  
BBB 
measurement 
methods   
In vivo  
In vitro  
Intra venous 
ART, PET, … 
In situ perfusion 
Cell based  
 Non cell based 
In silico  
Ex vivo 
Intra carotid 
Intra cerebral 
micro dialysis 
Brain derived 
cell cultures 
Non brain 
derived cell 
lines 
Co cultures 
Epithelial 
cell cultures 
(Caco2) 
Modified 
epithelial 
cell cultures PAMPA 
Linear 
Statistical 
Mechanistic 
IAMs 
Non linear 
Linear 
Non linear 
Primary brain 
epithelial cell 
cultures 
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Fig. 5. Different equilibria in brain.  
4.1.2 The importance of free drug measurement 
The free drug is responsible for pharmacokinetic and pharmacodynamic properties of drugs 
and relation between dose and response is correct when free drug supplies in target tissue 
get into account. In this regard interstitial fluid and intra cellular fluid drug levels in brain 
are important data for drug discovery.  
The traditional methods of brain homogenization destroy all compartments of brain 
(including brain tissue binding and plasma protein binding) and drug levels in specific 
compartments cannot be measured (Reichel, 2009). The plasma free fractions data cannot be 
used in CNS drug discovery studies, because of the different physiological properties, blood  
brain interstitial fluid free fractions. Some researchers used cerebrospinal drug levels (CSF 
sampling) as an estimate of the unbound drug levels in brain which is not so reliable 
because of lower tightness of cerebra-spinal blood barrier which leads to higher diffusion 
and overestimation of free drug concentration in brain (Read & Braggio, 2010). The 
microdialysis is the only in vivo method to provide such data directly, which is limited by its 
practicability. 
4.1.3 The rate and extent of drug penetration to the brain 
Neuropharmaceuticals should be able to permeate the BBB and enter the brain parenchyma 
in order to treat desired disorders whereas peripheral drugs should have limited entrance to 
the brain in order to decrease their neurological side effects. The drug entrance to the brain 
was evaluated and quantified using different methods, among them BUI, logBB, Kp,uu etc, 
are well studied and frequently used to measure the rate and the extent of brain drug 
penetration (Jeffrey & Summerfield, 2010).  
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Brain uptake index (BUI%) is one of the earliest indicators of BBB permeability of 
compounds and is calculated by: 
 % 100
ref
E
BUI
E
  (1) 
where E denotes the first pass extraction and the Eref referred to freely diffusible internal 
standard. This indicator provides information about the total concentration of the drug in 
the brain at early time point after administration (Lanevskij et al., 2010). 
The logBB which describes the ratio between brain and blood (or plasma) concentrations 
and provide a measure of the extent of drug permeation is calculated using (Kerns & Di, 
2008): 
 log tot.brainp
tot. blood
AUC 
BB or K  
AUC 
  (2) 
The only information provided by Kp is passive lipid partitioning of the drug which is 
affected by metabolism, relative binding affinity to proteins and lipid content of brain and 
blood or plasma and it is not a net measure of BBB permeability (Abbott, 2004; Mehdipour & 
Hamidi, 2009). It is highly time dependent and in order to get an overall estimation, usually 
is measured under steady-state conditions. 
Another approach based on unbound drug fraction, for quantifying the extent of brain 
penetration is recommended, which is calculated by:  
  u, brain
u, blood
 
    
 
p,uu
AUC
K   
AUC
  (3) 
Kp,uu affected by both passive diffusion and active influx/efflux and can give information 
about the permeation mechanism, beyond these, it is not affected by plasma protein and 
brain tissue binding which interfere in logBB values (Mehdipour & Hamidi, 2009). For drugs 
delivered by passive diffusion, this index will be close to unity while for efflux and influx 
substrates it will be less than and more than unity respectively (Hammarlund- Udenaes et 
al., 2008).  
To assess the brain drug permeability rate, the unidirectional influx constant from blood to 
the brain (Kin) and the product of the BBB permeability surface area (PS) which is a measure of 
the unidirectional clearance from blood to brain have been developed. Both parameters 
expressed as ml/min/g of brain (Rooy et al., 2010). PS is able to reflect the BBB permeation 
step more accurately (Abbott, 2004) and is valuable parameter for follow up permeation ability 
of drug candidates in the pharmaceutical industry and although in pathologic conditions. PS 
gives an estimation of unbound drug in brain but it is affected by the possible association of 
the drug with active influx or efflux transporters (Hammarlund- Udenaes et al., 2008).  
According to the measurement method Kin and PS can be calculated from Crone-Renkin 
equation: 
 1
PS
F
inK F e
     
 (4) 
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where F could be considered as perfusion flow rate, or cerebral blood flow rate and PS is 
computed using:  
 ln 1 in
K
PS F
F
        (5) 
Methods for measuring efflux of the drugs out of the brain (brain efflux index (BEI)) have 
been developed which represent the elimination rate constant of the drugs in brain. Using 
these parameters, scientists can provide information about the mechanism of BBB 
permeation in which for passive diffusion the efflux and influx constants will be similar.  
To measure all of these data, the remained drug in brain microvascular should be calculated 
and subtracted from total brain concentration.  
4.2 In vivo  
The resulted data from in vivo experiments are valuable and regarded as gold standard in 
CNS drug discoveries. This value comprises from the experiment which uses anesthetized 
or cautious animals which represent full physiologic condition for study and the obtained 
data reflect different aspects of BBB permeation. Demanding skilled scientists and equipped 
laboratories are the main disadvantage of these techniques.  
4.2.1 Intra venous injection 
Intra venous injection methods have been developed during primary CNS studies in order 
to assess the BBB permeability and brain distribution of the CNS drug candidates. The 
radio-labelled compounds are injected intravenously and blood samples are obtained in 
different time intervals and a single brain tissue can be obtained at the designated time 
point. The measured compound concentrations in plasma and brain plotted against the time 
and after calculating AUC values the logBB computed using equation 2. For each time 
interval three animals are needed and in order to get a plot using 7 data points, 21 animals 
are required which is the main limitation of the method (Rooy et al., 2010). The logBB are 
interesting for pharmaceutical companies, because they can be easily used to rank the goals 
and other pharmacokinetic parameters such as Cmax and time length that the compound 
remains above in vitro determined effective concentration can be calculated. Recently these 
data are questioned about their ability to reflect the permeability properties of studied 
compounds mainly because: 1) The obtained concentrations are total, while the free fraction 
of the compounds are responsible for most of their pharmacokinetic properties and 2) It is a 
brain distribution value and the permeation rate of compounds cannot be obtained (Kerns & 
Di, 2008). The other parameters which can be calculated using the obtained data are rate 
parameters (i.e. Kin and PS).  
4.2.2 Single carotid injection 
Single intra carotid injection is one of the earliest BBB permeation study methods and can be 
done by injection of a given concentration of a labelled compound through common carotid 
artery of an animal along with a reference standard and experiment stopped after 5 - 15 
seconds. Then the brain sampling is done and the brain uptake index (BUI%) can be 
calculated using the concentration of the compound and the reference standard (Pardridge, 
2007). Because of the low sensitivity of the method (limited sampling time), this method has 
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been replaced by in situ brain perfusion which provide higher control on experimental 
condition (Kerns & Di, 2008). 
4.2.3 In situ brain perfusion  
The desired concentration of the studied drug was prepared using the perfusion fluid and 
the resulted solution is perfused directly to the brain through common artery of an 
anesthetized animal (commonly rat) for the suitable time and the brain sampling carry out 
on the predefined time intervals after stopping the perfusion (Amith & Allen, 2003). Similar 
to the intravenous injection method the remained intravascular perfusion fluid should be 
removed by brain flashing or calculated using an impermeable compound injection (Rooy et 
al., 2010). Direct perfusion enables scientists to study the BBB drug permeation in the 
absence of the first pass metabolism or drug elimination methods. Using this method, the 
mechanism of drug permeation can be studied using co-administered transporter inhibitors. 
But such as intravenous injection high resource demanding is a limitation for this method. 
The Kin and PS can be calculated using the obtained data from this method.  
4.2.4 Quantitative auto radiography  
Another method for CNS drug partitioning study is quantitative auto radiography which 
can be used for regional study of total drug exposure. Using this method, the amount of 
radio labelled compound is measured in desired regions (e.g. stroke affected areas, brain 
tumours) following oral, intravenous or subcutaneous administrations to animals. Similar to 
previous methods after blood sampling in various time intervals, the brain is taking out and 
after sectioning the frozen brain to suitable sections the radioactivity is measured. Intra 
vascular correction is needed here too. Obtaining the regional PS values is possible using 
this method and the resolution of obtained data is high because of the micrometer 
dimensioned studied sections (Bickel, 2005; Rooy et al., 2010).  
4.2.5 Positron emission tomography  
Positron emission tomography is a non-invasive method which is applicable in human. The 
suitable tracers are administered to the body and the emission is monitored using positron 
emission tomography scanners. The blood sampling is done in designed intervals and the 
brain and plasma distribution is measured using a curve fitting method. Similar to 
quantitative auto radiography the regional information about drug distribution is 
achievable using this method (Dash & Elmquist, 2003).  
4.2.6 Intra cerebral microdialysis 
Microdialysis is the only technique which is able to provide the concentration of CNS drug 
candidates in the interstitial fluid directly. A stereotaxic probe equipped with a semi 
permeable membrane implanted under anesthesia. The interior of the probe perfused with a 
physiological solution and samples are taken from freely moving animals and analyze using 
suitable separation techniques (commonly chromatographic systems) (Bickel, 2005; Alivajeh 
& Palmer, 2010). The studied compound can be administered orally, intravenously, 
subcutaneously or from other routes. This method is applicable for human and by 
implanting the probe in different regions of brain; specific data from different parts of brain 
(which have different properties) could be collected. The recovery of the probe is an 
important point in this method to get the absolute concentration data. Pharmacokinetic 
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parameters of CNS drug candidates including half-life, Cmax, Tmax, total exposure, volume of 
distribution, clearance, BBB influx and efflux rates for different brain regions and most 
importantly the Kp,uu at steady state can be obtained and calculated using microdialysis 
driven data. These data can be used for pharmacodynamic studies and dosing regimens 
(Alivajeh & Palmer, 2010).  
The methods reviewed in sections 4.2.1 to 4.2.6 give information about the overall exposure 
resulted from different passive or active influx and efflux systems.  
4.2.7 Permeation mechanism study in vivo 
During drug development the detailed information about the mechanism of permeation and 
possible efflux or metabolic instability are needed to design the structure of the desired drug 
and its delivery system. To get detailed information researchers have been used different 
methods such as: knockout or gene deficient animals for studying the effect of a specific 
transporter, special enzyme or transporter inhibitors (e.g. efflux inhibitors) or receptor 
antagonists to eliminate the desired transport effect from the study.  
In order to study passive diffusion of drug candidates without interfering of other 
permeation mechanisms, a number of methods have been developed. For example, it is 
possible to use excess molar of unlabelled compound in order to saturate the transporters, 
enzymes or facilitated mechanisms. Also it is possible to use efflux transporters’ inhibitors 
(e.g verapamil for P-gp). Beside these, by studying the Michaelis-Menten behaviour of 
drugs, it is possible to ensure that the permeation mechanism is passive diffusion 
(unsaturable) or not.  
4.2.8 Ex vivo 
Ex vivo experiments are developed to study drug candidates more reliably out of the body in 
the simulated physiologic condition (pH, temperature, buffer, nutrients, oxygen) which 
have the advantage of being applicable in post mortem human samples obtained by 
autopsy. The resulted data from these experiments have been shown acceptable correlation 
with in vivo experiments. Although in this method impossible experiments and studies in 
living organism can be conducted, but the differences between the living organism and the 
slices obtained by autopsy according to the degradation of some proteins should be take 
into account (Cardoso et al., 2010).  
4.3 In vitro 
In order to do more rigorous investigations on the complex mechanisms occurred in 
endothelial cell membranes and in intracellular compartments (e.g. active and passive 
efflux and influx) in the BBB of a living organism, in vitro methods can be used. In vitro 
models of BBB should be simple, reproducible and mimic the in vivo conditions (both 
normal and pathologic). Most of the in vitro models of BBB are based on endothelial cells 
as the foundation of BBB and different animals are used to prepare cell cultures. The 
results should be interpret carefully because of the differentiations (the lower tightness of 
the developed cell lines, the phenotype modification and the absence of intercellular 
contact and in vivo signallings occur during the cell isolation). But it is a reliable method 
for high throughput screening experiments, in order to compare the penetration ability of 
a set of compounds (Cardoso et al., 2010). The main categories of in vitro models include 
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cell based and non cell based methods. Cell based models are simplification of in vivo 
system in which the brain and non brain derived cell cultures are used to study the 
permeation and transport of drug candidates. The brain derived cell cultures (primary 
endothelial cultures) show closest phenotype to the in vivo brain while their preparation 
and handling are more difficult than non-brain derived cell lines. Primary endothelial 
cultures prepared by isolating animal brain micro vessels and seeding in culture medium 
where the endothelial cells grow out and make suitable mono layers for experiments. In 
order to mimic the in vivo system more closely co-cultures included astrocytes have been 
developed which provide more physical and physiological features in comparison with 
primary cell cultures (Cardoso et al., 2010). Non brain derived models use the epithelial 
cell cultures (e.g. Caco 2) and modified epithelial cell cultures which are used for drug 
absorption studies in order to rank the permeability of CNS drug candidates. Non cell 
based in vitro models include the parallel artificial membrane permeability assay 
(PAMPA) and immobilized artificial membranes (IAMs) which used as HPLC columns 
and mimic the properties of biological membrane (Abbott, 2004). PAMPA models initially 
developed for study passive oral absorption and successfully applied in the 
pharmaceutical industry. Recently, it has been modified for using in BBB permeation 
studies and showed good correlation with in vivo findings (Mensch et al., 2010).  
4.4 BBB permeation prediction methods (in silico methods) 
In vivo, ex vivo and in vitro methods of assessing brain drug penetration leads to high quality 
data resemble most of the permeation mechanisms in BBB, but they are highly cost and time 
demanding and are not suitable for screening of large compound libraries. As soon as BBB 
studies have begun, attempts to predict the BBB permeation properties of drug candidates 
lead to primary structure activity relationships which later accepted as essential rules of 
CNS drug development. These structural features later used to develop quantitative 
relationships to predict the pharmacokinetic properties of CNS drugs. During years and 
improving the knowledge about the effect of different passive and active mechanisms of 
brain drug penetration, the prediction models improved and specific models to predict 
different aspects of BBB permeation have been developed. In order to develop a model first 
the prediction endpoint (dependent variable or experimental value) should be measured or 
obtained from the literature. The quality of these data is deterministic for developed model 
certainty. After selection of the data set, the inclusion of each point in data set should be 
evaluated and possible outliers should be determined. The next step is to split data set in 
training and test sets and measure or calculate the desired independent descriptors. The 
significant descriptors should be selected and the relationship between the dependent and 
independent variables should be developed using appropriate modelling method. While the 
model has been developed, its predictive ability along with other validation parameters 
should be calculated and the effect of selected descriptors on the experimental value should 
be defined. The details of each step are provided in following sections. Some commercial 
software have been developed to predict the brain drug penetration which can be used to 
get primary estimations about the CNS activity of a compound. 
4.5 Prediction endpoints (Experimental data) 
In order to get initial information about the BBB permeation of new drug entities, studying 
the existing information using different methods is more interesting than experimental 
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measurement. There are different (in vivo or in vitro) indicators which are able to evaluate 
the rate or extent of drug permeation to the BBB (see section 4.1.3). Among them logBB 
values have been used extensively for in silico methods in order to predict the extent of drug 
penetration to the brain and the related data sets can be found in the literature. Unbound 
drug fraction, logPS and BUI% have been used to develop the prediction methods, while some 
researchers used in vitro data (e.g. PAMPA derived P-gp binding affinity) for their studies 
(Dagenais et al., 2009). Beside these BBB+/- and CNS+/- data which have been extracted from 
logBB experiments and implications of brain disorders or targets about primary site of action 
of compounds respectively, were utilized for classification purposes (Klon, 2009). It seems that 
using the combined information derived from different indicators will be more useful than 
individual ones. The quality of selected data set should be considered according to the 
experimental method which used to obtain it (data set homogenesity). The homogenesity of 
logBB data sets have been questioned, but the studies showed that these combined data sets 
are applicable. Also the outliers should be determined using statistical methods or according 
to the experimental method. One of the most common statistical methods is to compute 
deviations of a single data point from mean dependent or independent variables or both of 
them and exclude highly deviated datum. In fact an applicability domain for each prediction 
method should be defined and the compounds out of this domain should be excluded from 
analyses. For experimental procedures it should be kept in mind that if special efflux inhibitors 
are used or not. In some methods, scientists are used unlabeled substrate to saturate the 
desired enzyme or transporter or receptor and the resulted data from these experiments 
should not be combined with others (Lavnevskij et al., 2010). The third point which should be 
kept in mind is that the number of the data points should be enough for developing statistical 
properties (e.g. regression coefficients) of the developed model and also for excluding a part of 
data as test set. If it is not possible the prediction capability of developed model cannot be 
evaluated and it will be applicable for the entire data set.  
4.6 Descriptors  
The structural features and physicochemical properties (Table 2) of the studied compounds 
should be extracted using the available experimental and computational methods 
(commercial software, fragment based methods, …). The most studied and evaluated 
descriptors to define the BBB permeation are those related with passive diffusion. Table 3 
contains the details of most frequently used descriptors as well as their effects on BBB 
permeation. As can be seen from the table, the overall findings about the structural features 
(also known as the rule of five) of the CNS drug candidates are: 
- High lipophilicity 
- Low hydrogen binding 
- Small molecular weight. 
It should be noted that these rules should be used cautiously during drug design procedure. 
For example, although high lipophilicity increase the permeation rate but it causes the poor 
solubility, metabolic instability and higher membrane bounding which are not suitable 
properties for a drug candidate.  
 
Descriptor 
Topological descriptors Constitutional, Molecular properties, Quantum 
chemical, ACDLabs, free aqueous solubility energy  
Software  Absolve, Dragon, Hyperchem, Volsurf, MOE, Cerius package  
Table 2. Frequently used descriptors and software. 
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Property  The cutoff for BBB permeation
Molecular weight < 400-500 Da 
H bond donor <3 
H bond acceptor <7 
ClogP* <7 
logD7.4 1-3 
Polar surface area < 60-70 A°2 
Rotatable bonds <8 
Flexibility 1.27 
pKa 7.5-10.5 
N+O <6 
* The studies showed that logPoct/water have poorer correlation with permeation data in comparision 
with ΔlogP or logD7.4. Recent studies showed that the ionization state of drug candidates in 
physiologic condition should be defined and the models should be developed accordingly (Lavenskij et 
al., 2009, 2010; Shayanfar et al., 2011).  
Table 3. Descriptors used in rules of five methods and their cut off points (Di, 2008; Palmer, 
2010) 
4.7 Model development  
After preparing a number of descriptors, the best descriptor or a combination of descriptors 
which are able to describe the desired dependent variable (prediction end point) should be 
selected. There are two approaches for descriptor selection: 
4.7.1 Mechanistic approach 
In this method, the studied property (e.g. BBB permeation) affecting parameters should be 
extracted from theoretical findings (several processes include in the overall result) and 
convert to mathematical representations. The provided descriptors depend on their effects 
(positive or negative, direct or inverse) on desired property should be correlated to the 
prediction end point and the resulted equation could be used for prediction purposes 
(Lavenskij et al., 2010).  
4.7.2 Statistical approach  
It is so important to exclude insignificant descriptors to prevent over fitting and biased 
results using a descriptor selection method. The number of descriptors depends on the 
modelling method. For simple multivariate regression methods, the number of descriptors 
depends on the number of data points, while for partial least square and principal 
component analyses methods it is not limited. In addition to the number of the descriptors 
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and their significances, the inter correlation between them should be checked and just one of 
the highly correlated descriptors should be kept in multiple linear regression methods, 
while this is not a problem for partial least square or principal component analyses. There 
are different methods for descriptor selection and more information can be found in the 
literature. It is better to keep the penetration mechanisms and approved relationships in 
mind in this step and avoids complete statistical methods.  
4.8 Method development 
As soon as the descriptors selected or provided in mechanistic approach, the model should 
be developed according to the purpose of the modelling. The in silico methods developed for 
following purposes in CNS drug studies: 
4.8.1 Classification  
It is important to know that if the desired compound is CNS active or not. To do this a 
border value should be defined for the scaled dependent variable. Different data sets have 
been used for these models: 
- logBB data (BBB+/-),  
- CNS active or inactive compounds (CNS+/-)  
- P-gp substrate or non-substrate (Pgp+/-). 
These models are applicable for screening studies (primary steps of CNS drug development) 
where the goal is to select the possible CNS active compounds from large compound libraries 
and in advanced steps of CNS drug studies where the possible reasons of efficacy failure are 
investigated. Different classification methods have been developed until now using different 
algorithms and descriptors. The review of these studies showed that the methods were more 
successful for CNS+ and BBB+ compounds than CNS- and BBB- ones. One reason for this 
approach is raised from efflux pumps which efflux some structurally suitable compounds 
from brain. Considering the efflux system substrates during method development will 
improve the prediction accuracy for these compounds. It should be noted that there is a 
difference between BBB+ and CNS+, since a drug could be penetrated into brain without 
measurable biological effect. However in some modelling studies these data were mixed up. It 
seems that in order to develop more accurate classifiers, some physiological properties of brain 
such as the extent of non-specific protein and tissue binding, the concentration of the target 
protein and specific receptors in the brain should be considered.  
4.8.2 Permeability prediction (The rate and extent of penetration) 
The logBB, Kp,uu (for exposure extent studies) and logPS (for rate studies) have been 
frequently used to develop prediction models. The multiple linear regression and least 
square methods are among the most studied models providing simple and interpretable 
equations.  
Detailed review of these equations could be found in the literature (Garg et al., 2008; Klon, 
2009; Mehdipour & Hamidi, 2009; Shayanfar et al., 2011). The descriptors used for rules of 
five (Table 3) studies originally comprised from these equations and at least one of these 
descriptors or similar descriptors which provide relevant information can be found in these 
equations. In this regard, most of the time, medicinal chemists use the same descriptors to 
check the new data set or new methods. Lipophilicity descriptors, size and shape 
descriptors, ionization states of compounds, and polar surface area descriptors proved to 
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have effect on BBB permeation. The complexity of BBB permeation encouraged scientists to 
check non linear methods applicability in this field and some exponential linear equations 
and neural networks have been successfully developed. Although neural networks 
provided more accurate predictions in comparison with linear ones, their interpretation and 
reproducibility are in question and their usefulness for developing universal models which 
can be applicable for chemists have not been approved yet. In fact the best model for a 
chemist is a model which is able to answer him/her what is the possible modification for 
desired property improvement and the un-interpretable models are not able to answer this 
question. Because of this, using less accurate but well defined models are preferred to 
complicate but accurate ones.  
The studies of unbound fraction of the drug in brain (Kp,uu) showed that the previously 
accepted trend of permeation (higher permeation for more lipophilic compounds) which 
was raised from logBB and logPS studies are not the same for unbound fraction, and 
lipophilicity have inverse relation with it. These findings showed that the absolute values 
for the effective descriptors are not suitable and a balanced range of descriptors should be 
defined for them (Lavenskij et al., 2010).  
4.9 Validation 
In order to check the sensitivity, specificity, prediction capability, reproducibility, error 
margins and chance correlations for the developed models, some validation statistics should 
be provided and using these parameters researchers will be able to make decision on selecting 
or rejecting a model in comparison with others. The details of these parameters and their 
usefulness for evaluating the model have been reviewed. For classification methods the lower 
failure in localization of compounds (both positive and negative) is better and for predictive 
models the higher correlation coefficients (both for training and test sets and cross validation 
sets), lower prediction errors (less than about 1 log unit deviation and relative mean squared 
errors less than 0.3)and lower correlation coefficients (e.g. <0.2) for Y randomized data sets are 
acceptable. These parameters are not absolute and it would be possible to accept a low quality 
model in the absence of the better one.  
4.10 Prediction using commercial software 
Using the developed models, some software has been developed in order to calculate the 
BBB permeation or P-gp binding affinity which can be used for estimation of compound 
permeation. These predictions are included in the most of the ADME prediction software 
which could be found on internet.  
5. Conclusion  
The importance of BBB for reaching CNS drugs to their targets and also undesired 
penetration of non CNS drugs to avoid their CNS side effects are briefly discussed. Short 
review of measurement methods of drug's penetration to CNS is presented along with a 
summary of computational aspects used for modelling purposes.  
The molecular and cellular properties of BBB have been reviewed and the role of its 
compartments in the regulating of drugs and xenobiotics penetration to the brain has been 
discussed. Working as a regulatory interface BBB is able to work as a physical and 
physiological barrier which prevents peripheral drugs to penetrate the brain and reduce 
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their CNS side effects. This barrier activity causes some difficulties in CNS drug delivery 
and different measurement methods have been developed to study the rate and extent of 
drug delivery to the brain and the mechanism of delivery methods have studied using these 
methods. Beyond the experimental methods, prediction of these properties are studied in 
order to provide cheaper, simpler and more rapid methods for medicinal chemists who 
work in brain drug development field.  
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